Melina Elpi Marmarelis, MD
Medical Oncology, Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
View 1 additional location
Headshot of Melina Elpi Marmarelis, MD
Penn Medicine Provider

About me

  • Medical Director, Penn Mesothelioma Program
  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Harvard Medical School
  • Residency: Mass General Brigham Healthcare Center - Chestnut Hill
  • Residency: University of Pennsylvania Health System

What my patients think about me

Average Rating

437 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
March 2026
very prompt and well prepared to deliver my status.
Anonymous
March 2026
they were very patient and thoughtful.
Anonymous
March 2026
very professional and very responsive
Anonymous
February 2026
she is extremely knowledgeable, listens and advises. she helps me feel confident that my treatment plan is the best choice for me.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Marmarelis is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Benjamin A. Bleiberg, Dylan G. Scholes, Lauren Reed-Guy, Devaki Dravid, Lova L. Sun, Aditi P. Singh, Roger B. Cohen, Corey J. Langer, Melina E. Marmarelis, Charu Aggarwal The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing , The Journal of Liquid Biopsy, 12: 2026


Benjamin A. Bleiberg, Lauren Reed-Guy, Roger B. Cohen, Charu Aggarwal, Corey J. Langer, Aditi P. Singh, Melina E. Marmarelis Carboplatin plus Pemetrexed versus Pemetrexed alone in Advanced Thymoma and Thymic Carcinoma: A Retrospective Cohort Study , Frontiers: 2026


Cole Friedes, Michelle Iocolano, Nikhil Yegya-Raman, John C Kucharczuk, Taine T V Pechet, Roger B Cohen, Charu Aggarwal, Melina E Marmarelis, William P Levin, Keith A Cengel, Christine A Ciunci, Christopher D'Avella, Aditi P Singh, Christiana W Davis, Corey J Langer, Jeffrey Bradley, Steven J Feigenberg Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy , American Journal of Clinical Oncology: 2026


Teja Voruganti, Christiana Davis, Melina E. Marmarelis, Charu Aggarwal Illusion of Comprehensive Testing in Non–Small Cell Lung Cancer: Why Coverage, Sensitivity, and Reporting Matter , JCO Oncology Practice: 2026


Melina E. Marmarelis, Adrienne M. Gilligan, Tomoko Sugihara, Shen Zheng, Tyler Marquart, Samuel Whipple, Naleen Raj Bhandari, Charu Aggarwal Evaluation of Guideline-Recommended Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer Patients who underwent Next-Generation Sequencing Testing: Results from a Real-World Study , Cancer Treatment and Research Communications: 2026


Benjamin T. Cooper, Jeffrey D. Bradley, Sushma Patel, Michael A. Pritchett, Steven J. Feigenberg, Kevin C. Ma, Isaac Laniado, Melina E. Marmarelis, Matthew Scarlotta, Joshua K. Sabari, Yi-Wen Ma, Yina Kuang, Kiran Devisetty, Balaji Laxmanan, David M. DiBardino Novel Intratumoral Radioenhancer (JNJ -1900) with Chemoradiation and Consolidative Immunotherapy for Stage III Unresectable Non -Small Cell Lung Cancer (NSCLC): Early Outcomes from the Phase II CONVERGE Study , ELCC 2026 Poster: 2026


Adam Barsouk, Alec Heidlauf, Keshav Goel, Lynn Rushkin, Anna Anran Huang, Omar Elghawy, Connie Yu, Lucy Wang, David Yang, Martin Kurian, Lauren Reed-Guy, Lova Sun, Aditi Singh, Charu Aggarwal, Roger B. Cohen, Corey Langer, Melina E. Marmarelis Osimertinib Dose-Reduction and Survival in First-Line EGFR-Mutated mNSCLC , Lung Cancer, 213: 2026,108936


Michael Offin...Melina E. Marmarelis eVOLVE-02 SS5 Meso TiP Abstract entitled: Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line therapy for unresectable pleural mesothelioma (PM): Substudy 5 of the eVOLVE-02 phase 2 study. , ELCC March 2026: 2026


Pascale Tomasini, MD, MSc, Yongsheng Wang, MD, Yongsheng Li, MD, PhD, Enriqueta Felip, MD, PhD, Lin Wu, MD, Jiuwei Cui, MD, PhD, Benjamin Besse, MD, PhD, Alexander I. Spira, MD, PhD, Joel W. Neal, MD, Ph, Koichi Goto, MD, PhD, Christina S. Baik, MD, MPH, Melina E. Marmarelis, MD, Eiki Ichihara, MD, PhD, Yiping Zhang, MD, Jong-Seok Lee, MD, PhD, Se-Hoon Lee, MD, PhD, James Chih-Hsin Yang, MD, PhD, Sebastian Michels, MD, Zacharias Anastasiou, MS, Joshua C. Curtin, PhD, Xuesong Lyu, PhD, Janine Mahoney, BSN, RN, Levon Demirdjian, PhD, Craig S. Meyer, MS, PhD, MPH, Youyi Zhang, PhD, Isabelle Leconte, PhD, Patricia Lorenzini, MS, Roland E. Knoblauch, MD, PhD, Leonardo Trani, MD, Mahadi Baig, MD, Joshua M. Bauml, MD, Byoung Chul Cho, MD, PhD Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 , Journal of Clinical Oncology, 44(1): 2026,54-65.


Melina E. Marmarelis, Meijia Zhou, Sajjad Raza, Qing Huang, Kiran Devisetty, Balaji Laxmanan, Rachael L. DiSantostefano, Iftekhar Kalsekar, Daniel Goomez Real-world Utilization and Outcomes with Pacific Regimen in Stage III Unresectable Non-small Cell Lung Cancer Patients: Results from a Multicenter US Database , ESMO Annual Meeting 2025: 2025